These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1331 related articles for article (PubMed ID: 16521130)

  • 21. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
    Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M
    Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Establishment of a real time quantitative-PCR assay for detection of TCR VgammaI-Jgamma gene rearrangement in acute lymphoblastic leukemia patients].
    Jiang XG; Xu B; Xu WJ; Li B
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):425-8. PubMed ID: 15355697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
    Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
    Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
    Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
    Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells?
    Schilham MW; Balduzzi A; Bader P;
    Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S49-52. PubMed ID: 15812531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
    Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
    Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
    Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
    Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G
    Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia.
    Ishaqi MK; Afzal S; Dupuis A; Doyle J; Gassas A
    Bone Marrow Transplant; 2008 Feb; 41(3):245-52. PubMed ID: 17952129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
    Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
    Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
    Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.
    Szczepański T; Flohr T; van der Velden VH; Bartram CR; van Dongen JJ
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):37-57. PubMed ID: 11987915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pattern of immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Polish pediatric acute lymphoblastic leukemia patients--implications for RQ-PCR-based assessment of minimal residual disease.
    Dawidowska M; Derwich K; Szczepański T; Jółkowska J; van der Velden VH; Wachowiak J; Witt M
    Leuk Res; 2006 Sep; 30(9):1119-25. PubMed ID: 16476479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival.
    Jacobsohn DA; Tse WT; Chaleff S; Rademaker A; Duerst R; Olszewski M; Huang W; Chou PM; Kletzel M
    Br J Haematol; 2009 Sep; 146(6):669-74. PubMed ID: 19650884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
    Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimerism after allogeneic hematopoietic cell transplantation in childhood acute lymphoblastic leukemia.
    Ramírez M; Díaz MA; García-Sánchez F; Velasco M; Casado F; Villa M; Vicario JL; Madero L
    Bone Marrow Transplant; 1996 Dec; 18(6):1161-5. PubMed ID: 8971389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.